Recombinant antibodies and recombinant proteins produced by evitria find applications in various research endeavors. On this page you will see a selected list of peer-reviewed publications that reference evitria.
We would appreciate hearing from you if you have already published or intend to publish your work.
2023
| Künzi, Lisa, et al. “Transport of Designed Ankyrin Repeat Proteins through reconstituted human bronchial epithelia and protection against SARS-CoV-2.” Scientific Reports 13.1 (2023): 5537. https://doi.org/10.1038/s41598-023-32269-1 |
| Daniels-Wells, Tracy R., et al. “Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma.” Cancers 15.6 (2023): 1816. https://doi.org/10.3390/cancers15061816 |
| Schellino, Roberta, et al. “Synergistically Acting on Myostatin and Agrin Pathways Increases Neuromuscular Junction Stability and Endurance in Old Mice.” Aging and Disease (2023): 1-18. https://doi.org/10.14336/AD.2023.0713-1 |
| Trikeriotis, Markos, et al. “Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability.” Pharmaceutical Research 40.2 (2023): 487-500. https://doi.org/10.1007/s11095-022-03448-y |
| Gytz Olesen, Heidi, et al. “Development, characterization, and in vivo validation of a humanized C6 monoclonal antibody that inhibits the membrane attack complex.” Journal of Innate Immunity 15.1 (2023): 16-36. https://doi.org/10.1159/000524587 |
| Lavy, Margot, et al. “ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.” Frontiers in Immunology 14 (2023). 10.3389/fimmu.2023.1196731 |
| Haake, Markus, et al. “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.” Nature Communications 14.1 (2023): 4253. https://doi.org/10.1038/s41467-023-39817-3 |
| Verbruggen, Christina, et al. “CARs are organized in nanodomains in the plasma membrane of T cells that accumulate at tumor contact sites.” bioRxiv (2023): 2023-07. https://doi.org/10.1101/2023.07.19.549702 |
| Noverraz, François, et al. “Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody.” International Journal of Pharmaceutics 630 (2023): 122463. https://doi.org/10.1016/j.ijpharm.2022.122463 |
| Melo V, Nelemans LC, Vlaming M, et al. “EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells.” Frontiers in Immunology 14 (2023):1191866. |
| Ortega-Ferreira, Céline, et al. “Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.” Nature Communications Aug 14 (1) (2023): 5291. https://doi.org/10.1038/s41467-023-41117-9 |
| Aquino, Yann, et al. “Dissecting human population variation in single-cell responses to SARS-CoV-2.” Nature Sep 621 (7977) (2023):120-128. https://doi.org/10.1038/s41586-023-06422-9 |
| van Hooren, Luuk, et al. “CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma.” Nature Cancer May 4 (5) (2023): 665-681. https://doi.org/10.1038/s43018-023-00547-6 |
| Lavy, Margot, et al. “ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.” Front Immunol. Jul 19. 14 (2023):1196731. https://doi.org/10.3389/fimmu.2023.1196731 |
| Melo, Vinicio, et al. “EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells.” Front Immunol. Jul 20. 14 (2023):1191866. https://doi.org/10.3389/fimmu.2023.1191866 |
| Andrew D. Steele, “Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships.” Journal of Medicinal Chemistry 66 (2) (2023): 1562-1573. https://doi.org/10.1021/acs.jmedchem.2c01771 |
| Basile, Anna, et al. “L. Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.” Antiviral Res. Mar 211 (2023):105546. https://doi.org/10.1016/j.antiviral.2023.105546 |
| Generalov, Roman, et al. “NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL.” bioRxiv 2023.07.12.548667. https://doi.org/10.1101/2023.07.12.548667 |
2022
| Zakrzewicz, Anna, et al. “Stabilization of keratinocyte monolayer integrity in the presence of anti-desmoglein-3 antibodies through FcRn blockade with efgartigimod: novel treatment paradigm for pemphigus?.” Cells 11.6 (2022): 942. https://doi.org/10.3390/cells11060942 |
| Fayd’herbe De Maudave, Alexis, et al. “Intra-articular delivery of full-length antibodies through the use of an in situ forming depot.” Journal of Controlled Release 341 (2022): 578-590. https://doi.org/10.1016/j.jconrel.2021.12.010 |
| Plattner, Kevin, et al. “IgE glycans promote anti-IgE IgG autoantibodies that facilitate IgE serum clearance via Fc Receptors.” Frontiers in immunology 13 (2022): 1069100. https://doi.org/10.3389/fimmu.2022.1069100 |
| Ferrari, Mathieu, et al. “Structure-Guided Engineering of Immunotherapies Targeting TRBC1 and TRBC2 in T Cell Malignancies.” (2022). https://doi.org/10.21203/rs.3.rs-1475171/v1 |
| Mendes-Frias, Ana, et al. “Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines.” Scientific Reports 12.1 (2022): 17047. https://doi.org/10.1038/s41598-022-20852-x |
| Rothenberger, Sylvia, et al. “The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.” Nature biotechnology 40.12 (2022): 1845-1854. https://doi.org/10.1038/s41587-022-01382-3 |
| Brinkhaus, Maximilian, et al. “The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement.” Nature Communications 13.1 (2022): 6073. https://doi.org/10.1038/s41467-022-33764-1 |
| Rigamonti, Nicolò, et al. “A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression.” Cancer Immunology Research 10.5 (2022): 626-640. https://doi.org/10.1158/2326-6066.CIR-21-0553 |
| Sahin, Mehmet, et al. “Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.” Cell Reports 38.5 (2022). https://doi.org/10.1016/j.celrep.2022.110303 |
| Bozhanova, Galabina, et al. “CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.” Journal for immunotherapy of cancer 10.3 (2022). https://doi.org/10.1136%2Fjitc-2021-004410 |
| Birley, Kathleen, et al. “A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.” Molecular Therapy-Oncolytics 26 (2022): 429-443. https://doi.org/10.1016/j.omto.2022.08.008 |
| Meghnem, Dihia et al. “Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation.” Frontiers in Immunology 13 (2022): 886213. https://doi.org/10.3389/fimmu.2022.886213 |
| Mekkaoui, Leila, et al. “Efficient clinical-grade γ-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing.” Molecular therapy. Methods & Clinical Development Mar 28 (2023):116-128. https://doi.org/10.1016/j.omtm.2022.12.006 |
| Basile, Anna, et al. “A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.” bioRxiv (2022). https://doi.org/10.1101/2022.08.04.502768 |
| Choi, Yu-Ra, et al. “Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.” Cancers Mar.14(6) (2022):1512. https://doi.org/10.3390/cancers14061512 |
| Drouin, Marion, et al. “CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy.” Science Advances Nov 8(46) (2022):eabo7621. https://doi.org/10.1126/sciadv.abo7621 |
| Aquino, Yann, et al. “Environmental and genetic drivers of population differences in SARS-CoV-2 immune responses.” bioRxiv (2022) https://doi.org/10.1101/2022.11.22.517073 |
| D’Addio, Francesca et al. “The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.” Nature Communications Feb 13 (1) (2022):684. https://doi.org/10.1038/s41467-022-28360-2 |
| Arruda LCM, et al. “A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo</i>. ” Haematologica 107(8) (2022):1786-1795. https://doi.org/10.3324/haematol.2021.279486 |
2021
| Chauvin, Maëva, et al. “Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.” International Journal of Oncology 59.1 (2021): 1-14. https://doi.org/10.3892/ijo.2021.5223 |
| Stančič, Brina, et al. “The blood endothelial cell chamber–An innovative system to study immune responses in drug development.” International Immunopharmacology 90 (2021): 107237. https://doi.org/10.1016/j.intimp.2020.107237 |
| Reichen, Filip Radom, et al. “Multi-specific DARPin® therapeutics demonstrate very high potency against mutated SARS-CoV-2 variants in vitro.” |
| Chauvin, Maëva, et al. “Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells.” Scientific Reports 11.1 (2021): 2231. https://doi.org/10.1038/s41598-021-81819-y |
| Rothenberger, Sylvia, et al. “Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants.” bioRxiv (2021): 2021-02. https://doi.org/10.1101/2021.02.03.429164 |
| Stumpp, Michael. “Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants.” (2021). https://doi.org/10.21203/rs.3.rs-1170399/v1 |
| Caracciolo, Daniele, et al. “Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.” Journal for immunotherapy of cancer 9.2 (2021). https://doi.org/10.1136%2Fjitc-2020-002026 |
| Engeroff, Paul, et al. “Glycan-specific IgG anti-IgE autoantibodies are protective against allergic anaphylaxis in a murine model.” Journal of allergy and clinical immunology 147.4 (2021): 1430-1441. https://doi.org/10.1016/j.jaci.2020.11.031 |
| Knitz, Michael W., et al. “Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.” Journal for immunotherapy of cancer 9.4 (2021). https://doi.org/10.1136%2Fjitc-2020-001955 |
| Warmuth, Stefan, et al. “Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.” Oncoimmunology 10.1 (2021): 2004661. https://doi.org/10.1080/2162402X.2021.2004661 |
| Trilleaud, C., et al. “Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.” Science advances 7.14 (2021): eabd1453. https://doi.org/10.1126/sciadv.abd1453 |
| Biasco, Luca, et al. “Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.” Nature cancer 2.6 (2021): 629-642. https://doi.org/10.1038/s43018-021-00207-7 |
| Andrejeva, Gabriela, et al. “Novel SIRPα antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells.” The Journal of Immunology 206.4 (2021): 712-721. https://doi.org/10.4049/jimmunol.2001019 |
| Rinne, Sara S., et al. “HER3 pet imaging: 68Ga-labeled affibody molecules provide superior HER3 contrast to 89Zr-labeled antibody and antibody-fragment-based tracers.” Cancers 13.19 (2021): 4791. https://doi.org/10.3390/cancers13194791 |
| Marulanda, Juliana, et al. “Skeletal Effects of Bone-Targeted TGFbeta Inhibition in a Mouse Model of Duchenne Muscular Dystrophy.” Life (Basel, Switzerland). 2021 Aug;11(8):791. https://doi.org/10.3390/life11080791 |
| Chen, Tony J, et al. “AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.” Physiological Reports Dec 9 (23) (2021):e15140. https://doi.org/10.14814/phy2.15140 |
| Vergoossen, Dana LE, et al. “Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.” Proceedings of the National Academy of Sciences of the United States of America Mar118(13) (2021):e2020635118. https://doi.org/10.1073/pnas.2020635118 |
| Florent Amatore, et al. “Chimerized Anti-ICOS 314.8 Monoclonal Antibodies Inhibit Tumor Cells and Regulatory T Cells in Patients with Sézary Syndrome.” Blood 138 (Supplement 1) (2021): 2260. https://doi.org/10.1182/blood-2021-153345 |
2020
| Boido, Marina, et al. “A new protein curbs the hypertrophic effect of myostatin inhibition, adding remarkable endurance to motor performance in mice.” PloS one 15.3 (2020): e0228653. https://doi.org/10.1371/journal.pone.0228653 |
| Puro, Robyn J., et al. “Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding.” Molecular Cancer Therapeutics 19.3 (2020): 835-846. https://doi.org/10.1158/1535-7163.MCT-19-1079 |
| Solomon, Isabelle. Targeting regulatory T cells for therapeutic gain in cancer therapy. Diss. UCL (University College London), 2020. https://discovery.ucl.ac.uk/id/eprint/10094239 |
| Engeroff, Paul, et al. “CD23 provides a noninflammatory pathway for IgE-allergen complexes.” Journal of Allergy and Clinical immunology 145.1 (2020): 301-311. https://doi.org/10.1016/j.jaci.2019.07.045 |
| Brinkhaus, Maximilian, et al. “Glycine 236 in the lower hinge region of human IgG1 differentiates FcγR from complement effector function.” The Journal of Immunology 205.12 (2020): 3456-3467. https://doi.org/10.4049/jimmunol.2000961 |
| Solomon, Isabelle, et al. “CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.” Nature cancer 1.12 (2020): 1153-1166. https://doi.org/10.1038/s43018-020-00133-0 |
| Deveuve Q, Lajoie L, Barrault B, Thibault G. “The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.” Frontiers in Immunology.11 (2020):168. https://doi.org/10.3389/fimmu.2020.00168 |
| Śledzińska, Anna, et al. “Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.” Immunity Jan 52 (1) (2020):151-166.e6. https://doi.org/10.1016/j.immuni.2019.12.007 |
2019
| Basile, Anna, et al. “Development of an anti‐BAG3 humanized antibody for treatment of pancreatic cancer.” Molecular oncology 13.6 (2019): 1388-1399. https://doi.org/10.1002/1878-0261.12492 |
| Bruins, Jorick J., et al. “Highly efficient mono-functionalization of knob-in-hole antibodies with strain-promoted click chemistry.” ACS omega 4.7 (2019): 11801-11807. https://doi.org/10.1021/acsomega.9b01727 |
| Chauvin, Maëva, et al. “In Ovarian Cancer, the Concentration of Anti-Müllerian Hormone Dictates the Choice between Pro-Survival and Pro-Apoptotic Pathways Through Differential ALK2/ALK3 Usage.” Available at SSRN 3501841 (2019). http://dx.doi.org/10.2139/ssrn.3501841 |
| Ubah, Obinna C., et al. “An anti-hTNF-α variable new antigen receptor format demonstrates superior in vivo preclinical efficacy to humira® in a transgenic mouse autoimmune polyarthritis disease model.” Frontiers in Immunology 10 (2019): 526. https://doi.org/10.3389/fimmu.2019.00526 |
| Kuciak, Monika, et al. “Chimeric NANOG repressors inhibit glioblastoma growth in vivo in a context-dependent manner.” Scientific reports 9.1 (2019): 3891. https://doi.org/10.1038/s41598-019-39473-y |
| Huijbers, Maartje G., et al. “Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.” Experimental Neurology 317 (2019): 133-143. https://doi.org/10.1016/j.expneurol.2019.03.001 |
| Mackness, Brian C., et al. “Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.” MAbs. Vol. 11. No. 7. Taylor & Francis, 2019. https://doi.org/10.1080/19420862.2019.1633883 |
| Neiveyans, Madeline, et al. “A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.” MAbs. Vol. 11. No. 3. Taylor & Francis, 2019. https://doi.org/10.1080/19420862.2018.1564510 |
| Gamper, Coralie, et al. “Functionalized Tobacco Mosaic Virus Coat Protein Monomers and Oligomers as Nanocarriers for Anti-Cancer Peptides.” Cancers Oct 11(10) (2019):E1609. https://doi.org/10.3390/cancers11101609 |
| Koike, Kengo, et al. “Subcutaneous administration of neutralizing antibodies to endothelial monocyte-activating protein II attenuates cigarette smoke-induced lung injury in mice.” American Journal of physiology. Lung Cellular and Molecular Physiology. Mar 316(3) (2019):L558-L566. https://doi.org/10.1152/ajplung.00409.2018 |
| Binamé Fabien, et al. “Disruption of Sema3A/Plexin-A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination.” EMBO Molecular Medicine Nov 11(11) (2019):e10378. https://doi.org/10.15252/emmm.201910378 |
| Ghorashian, S., et al. “Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.” Nat Med 25, 1408–1414 (2019). https://doi.org/10.1038/s41591-019-0549-5 |
2018
| Ravi, Rajani, et al. “Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.” Nature communications 9.1 (2018): 741. https://doi.org/10.1038/s41467-017-02696-6 |
| Engeroff, Paul, et al. “Allergens displayed on virus‐like particles are highly immunogenic but fail to activate human mast cells.” Allergy 73.2 (2018): 341-349. https://doi.org/10.1111/all.13268 |
| Furness, Andrew JS. T cell reactivity and regulation in human cancer. Diss. UCL (University College London), 2018. https://discovery.ucl.ac.uk/id/eprint/10054776 |
| Ulrichts, Peter, et al. “Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.” The Journal of Clinical Investigation 128.10 (2018): 4372-4386. https://doi.org/10.1172/JCI97911 |
| Vargas, Frederick Arce, et al. “Fc effector function contributes to the activity of human anti-CTLA-4 antibodies.” Cancer cell 33.4 (2018): 649-663. https://doi.org/10.1016/j.ccell.2018.02.010 |
| Giansanti, Francesco, et al. “Strategies to improve the clinical utility of saporin-based targeted toxins.” Toxins 10.2 (2018): 82. https://doi.org/10.3390/toxins10020082 |
| Orlova, Anna, et al. “Evaluation of the therapeutic potential of a HER3-binding affibody construct TAM-HER3 in comparison with a monoclonal antibody, seribantumab.” Molecular Pharmaceutics 15.8 (2018): 3394-3403. https://doi.org/10.1021/acs.molpharmaceut.8b00393 |
| Ghorani, Ehsan, et al. “Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.” Cancer Cell 33 (2018): 1-15. https://doi.org/10.1016/j.ccell.2018.02.010 |
| Mailly, Laurent, et al. “In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.”Antiviral Research Feb162 (2018):136-141. https://doi.org/10.1016/j.antiviral.2018.12.018 |
| Madouri, Fahima, et al. “Production of Interleukin-20 cytokines limits bacterial clearance and lung inflammation during infection by Streptococcus pneumoniae.” Ebiomedicine Nov 37 (2018):417-427. https://doi.org/10.1016/j.ebiom.2018.10.031 |
| Marie Frutoso, et al. “Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles.” J Immunol 201 (2) (2018): 493–506. https://doi.org/10.4049/jimmunol.1800086 |
| Obinna C. Ubah, et al. “Next-generation flexible formats of VNAR domains expand the drug platform’s utility and developability.” Biochem Soc Trans 46 (6) (2018): 1559–1565. https://doi.org/10.1042/BST20180177 |
Find all publications back to 2013 on Google Scholar or Europe PMC.